Compare Torrent Pharma with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs DIVIS LABORATORIES - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA DIVIS LABORATORIES TORRENT PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 61.1 38.1 160.4% View Chart
P/BV x 7.2 7.1 101.1% View Chart
Dividend Yield % 0.9 0.9 98.6%  

Financials

 TORRENT PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-19
DIVIS LABORATORIES
Mar-19
TORRENT PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,9641,639 119.8%   
Low Rs1,2451,115 111.7%   
Sales per share (Unadj.) Rs453.4186.3 243.4%  
Earnings per share (Unadj.) Rs25.851.0 50.6%  
Cash flow per share (Unadj.) Rs62.357.3 108.7%  
Dividends per share (Unadj.) Rs17.0016.00 106.3%  
Dividend yield (eoy) %1.11.2 91.2%  
Book value per share (Unadj.) Rs279.2261.8 106.7%  
Shares outstanding (eoy) m169.22265.47 63.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.57.4 47.9%   
Avg P/E ratio x62.227.0 230.3%  
P/CF ratio (eoy) x25.824.0 107.2%  
Price / Book Value ratio x5.75.3 109.2%  
Dividend payout %65.931.4 210.0%   
Avg Mkt Cap Rs m271,513365,592 74.3%   
No. of employees `00013.611.8 114.8%   
Total wages/salary Rs m14,0385,423 258.9%   
Avg. sales/employee Rs Th5,642.64,175.1 135.1%   
Avg. wages/employee Rs Th1,032.4457.7 225.5%   
Avg. net profit/employee Rs Th320.91,141.8 28.1%   
INCOME DATA
Net Sales Rs m76,72849,463 155.1%  
Other income Rs m5711,556 36.7%   
Total revenues Rs m77,29951,019 151.5%   
Gross profit Rs m19,83118,718 105.9%  
Depreciation Rs m6,1771,689 365.7%   
Interest Rs m5,03835 14,392.9%   
Profit before tax Rs m9,18718,551 49.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5700-   
Tax Rs m1,2545,023 25.0%   
Profit after tax Rs m4,36313,527 32.3%  
Gross profit margin %25.837.8 68.3%  
Effective tax rate %13.627.1 50.4%   
Net profit margin %5.727.3 20.8%  
BALANCE SHEET DATA
Current assets Rs m50,37546,501 108.3%   
Current liabilities Rs m51,6538,468 610.0%   
Net working cap to sales %-1.776.9 -2.2%  
Current ratio x1.05.5 17.8%  
Inventory Days Days92131 70.4%  
Debtors Days Days6886 79.6%  
Net fixed assets Rs m83,64825,797 324.3%   
Share capital Rs m846531 159.4%   
"Free" reserves Rs m46,39768,962 67.3%   
Net worth Rs m47,24469,493 68.0%   
Long term debt Rs m39,1290-   
Total assets Rs m141,20980,383 175.7%  
Interest coverage x2.8531.0 0.5%   
Debt to equity ratio x0.80-  
Sales to assets ratio x0.50.6 88.3%   
Return on assets %6.716.9 39.5%  
Return on equity %9.219.5 47.4%  
Return on capital %12.326.7 46.1%  
Exports to sales %00-   
Imports to sales %024.6 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA12,187 0.0%   
Fx inflow Rs m22,10341,238 53.6%   
Fx outflow Rs m5,52212,405 44.5%   
Net fx Rs m16,58128,833 57.5%   
CASH FLOW
From Operations Rs m17,9819,543 188.4%  
From Investments Rs m-2,413-6,854 35.2%  
From Financial Activity Rs m-13,145-2,459 534.5%  
Net Cashflow Rs m2,380230 1,036.7%  

Share Holding

Indian Promoters % 71.5 52.0 137.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 11.8 59.5%  
FIIs % 12.6 19.0 66.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 17.2 51.2%  
Shareholders   26,511 31,796 83.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   DR. REDDYS LAB  IPCA LABS  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  STERLING BIOTECH  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Market Drivers, Key Q3FY20 Results, and Top Cues in Focus Today(Pre-Open)

On Wednesday, Indian share markets gave up early gains in the afternoon session and ended lower. Benchmark indices fell for the third day amid volatility in global markets.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

My Latest Stock Recommendation(Fast Profits Daily)

Jan 10, 2020

The story behind my latest stock recommendation and an important announcement.

Bet on These Smallcap Stocks for Success in 2020(Profit Hunter)

Jan 14, 2020

The smallcap rebound finally seems to here... Make sure you aren't too late to make the most of the biggest wealth making opportunity in a decade.

Guess Which Stocks Are Rising at Double the Speed of Sensex(Profit Hunter)

Jan 15, 2020

These stocks can move twice as fast as the Sensex - to take advantage of their money multiplying power get in now as the rally is still just taking shape.. read more to not miss out.

What the Infosys Results Tell Us About the Next Infosys(The 5 Minute Wrapup)

Jan 15, 2020

If you're interested in the next Infosys, I'll tell you where to look.

For 1,000%+ Gains, Follow the 8-Year Cycle in the Stock Market(Fast Profits Daily)

Jan 17, 2020

This is how the biggest trading profits are made.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Jan 22, 2020 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS